- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
- Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
- NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
- NeuroStar TMS Receives Expanded Regulatory Approval in Japan
- NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
- Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
- Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
More ▼
Key statistics
As of last trade Neuronetics Inc (STIM:NMQ) traded at 3.69, -27.22% below its 52-week high of 5.07, set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.69 |
---|---|
High | 3.69 |
Low | 3.69 |
Bid | 3.60 |
Offer | 3.71 |
Previous close | 3.75 |
Average volume | 69.52k |
---|---|
Shares outstanding | 29.97m |
Free float | 28.08m |
P/E (TTM) | -- |
Market cap | 112.40m USD |
EPS (TTM) | -1.06 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 14:30 BST.
More ▼